Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Hsu Untied Interview with Caine Moss, Partner at Goodwin (Hsu Untied Podcast)

main

announcements-lifesciences-hsu-untied-interview-partner-at-goodwin

Caine Moss, a partner in Goodwin's Technology group, was recently featured as a guest on Hsu Untied, a unique podcast with Richard Hsu.

Hsu Untied Interview with Caine Moss, Partner at Goodwin (Hsu Untied Podcast)

Related Content

First Circuit Adopts Defense-Friendly “But-For” Causation Standard for AKS-Predicated FCA Claims

FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes

IP Litigator Publishes Goodwin Partners’ BPCIA Research

UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine

Regulatory Updates on Samsung’s Denosumab Biosimilars

Dr. Reddy’s Secures License from Henlius to Market Daratumumab Biosimilar in the U.S. and Europe

Regulatory and Commercial Updates on Bio-Thera’s BAT2506 (golimumab)

HyClone Seeks to Quash Amgen’s Subpoena Issued in Denosumab BPCIA Litigation Against Fresenius

Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko

Bpifrance and Andera Partners Invest in the €27 Million Series B Financing of EG 427

Goodwin Advises Atrandi Biosciences in $25M Series A Financing

Stilla Technologies and the Sellers Sign a Put Option Agreement for the Acquisition of Stilla Technologies by Bio-Rad

Chambers Global 2025 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Anthos Therapeutics To Be Acquired by Novartis For Up To $3.1 Billion

Goodwin Paris Recognized by Chambers France 2025

Life Sciences

Technology